Dimension Therapeutics Announces Presentations Highlighting Advances in AAV Manufacturing at the European Society of Gene and Cell Therapy (ESGCT) Congress

Researchers Report on New Technologies to Support Current and Next Generation HELA 2.0 AAV Manufacturing Platform

CAMBRIDGE, Mass., Oct. 18, 2016 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the liver, a key organ for human metabolism, today announced three poster presentations that highlight the mammalian vector manufacturing platform for Dimension's novel clinical and preclinical product development programs. The presentations are taking place this week during the ESGCT Congress, which is being held in Florence, Italy, October 18-21, 2016.

In one poster, titled "Establishing a clone selection strategy to accelerate recombinant adeno-associated virus (rAAV) producer cell line development" (Poster #P368), Dimension researchers are reporting on a technique that reduces the time by 50% or more to create cell lines producing AAV vectors for use in in vivo preclinical studies and clinical trials. A second poster - "Particle Titer Determination and Characterization of rAAV Molecules Using Nanoparticle Tracking Analysis and Other Techniques" (Poster #P394) - disclosed a novel detection method that can measure therapeutic concentrations of an AAV therapeutic product in minutes, rather than in hours or days as required by traditional techniques. Additionally, Dimension research featured in a poster, titled "Molecular assay toolbox to identify characteristics of recombinant adeno-associated virus (rAAV)-producing cell lines" (Poster #P379), examined an array of techniques to determine molecular characteristics correlating with enhanced cell line productivity.

"The presentations at this year's ESGCT conference underscore Dimension's leadership in innovating next-generation manufacturing technologies for gene therapy products," said Dr. Annalisa Jenkins, MBBS, FRCP, Chief Executive Officer of Dimension. "We are committed to developing a new standard in the manufacturing of AAV vectors, one that supports the large scale and high quality we believe is required to unlock the full potential of this field."

About Dimension Therapeutics

Dimension Therapeutics, Inc. (NASDAQ:DMTX) is the leader in discovering and developing new therapeutic products for people living with devastating rare diseases associated with the liver, based on the most advanced, mammalian adeno-associated virus (AAV) gene delivery technology. Dimension is actively progressing its broad pipeline, which features programs addressing unmet needs for patients suffering from inherited metabolic diseases, including OTC deficiency, GSDIa, citrullinemia type 1, PKU, Wilson disease, a collaboration with Bayer in hemophilia A, and a wholly owned clinical program in hemophilia B. The company targets diseases with readily identifiable patient populations, highly predictive preclinical models, and well-described, and often clinically validated, biomarkers. Founded in 2013, Dimension maintains headquarters in Cambridge, Massachusetts.

For more information, please visit http://www.dimensiontx.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the development of new manufacturing processes, increased production and scale capacity. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include the risks that the benefits of new manufacturing processes will not be realized; Dimension's product candidates, including its lead candidate, DTX101, will not successfully be developed or commercialized; and the risks described under the caption "Risk Factors" in Dimension Therapeutics' Quarterly Report on Form 10-Q for the quarter ended June 30, 2016, which is on file with the Securities and Exchange Commission, as well as other risks detailed in Dimension Therapeutics' additional filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Dimension Therapeutics undertakes no duty to update this information unless required by law.

CONTACT: Jean Franchi Chief Financial Officer Dimension Therapeutics 617-714-0709 jean.franchi@dimensiontx.com Burns McClellan, on behalf of Dimension Therapeutics Media: Justin Jackson 212-213-0006, ext.327 jjackson@burnsmc.com

To read more Press Release articles, click here.